James E. Talmadge, Ph.D.

Department Affiliations
Professor

Interests
Tumor progression and metastasis, immune intervention in cancer using cytokines, vaccines and molecular therapeutics, regulation of myeloid derived suppressor cells (MDSCs), molecular and cellular immunology, hematology and stem cell transplantation, oncology, gene therapy, translational research

For further details of Dr. Talmadge's Laboratory of Transplantation Immunology, please visit his laboratory webpage.

Education and Training
B.S., Biology, Virginia Polytechnic Institute and State University at Blacksburg, VA, 1973
M.S., Bacteriology, Washington State University, Pullman, 1975
Ph.D., Veterinary Pathology, Washington State University, Pullman, 1979
Postdoctoral fellow, NCI-FCRF, Frederick MD, 1990
 
Teaching Activities
Biotechnology Today
BIOC 880 "Principles and Methodologies in Cancer Research" - Gene Therapy
Faculty Advisor for one Graduate Student

National Activities
Editor-In-Chief: International Immunopharmacology (1999 to present)
Associate Editor: J Immunopharmacology and Immunotoxicology, Cancer Gene Therapy, Current Medicinal Chemistry-Cardiovascular & Hematologic Agents (2001-present), Current Medicinal Chemistry (2004-present)
Chairman or member of Susan G. Koman, Congressionally Directed Medical Research Programs, and American Institute of Biological Sciences study sections, as well as numerous others
Recipient of the Mary Crowley Medical Research Center Excellence Award (2006)
Recipient of the iSBTc Team Science Award (2010)

Notable Publications
Talmadge JE.  2010.  Immunostimulants in Cancer Therapy. In: Principles of Immunopharmacology.  Ed. FP Nijkamp and MJ Parnham, Birkhäuser Publishing, Basel, Switzerland.  pp 345-368.

Talmadge JE, Fidler IJ.  2010.  AACR Centennial Series:  The Biology of Cancer Metastasis:  Historical Perspective.  Cancer Res 70:5649-69.

Abe F, Younos I, Westphal S, Samson H, Scholar E, Dafferner A, Hoke TA, Talmadge JE.  2010.  Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice.  Int Immunopharmacol 10:140-55.

Talmadge, JE.  2010.  Models of metastasis in drug discovery.  Methods Mol Biol 602: 215-33.

Abe F, Dafferner AJ, Donkor M, Westphal SN, Scholar EM, Solheim JC, Singh RK, Hoke TA, Talmadge JE.  2010.  Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice. Cancer Immunol Immunother 59:47-62.

Talmadge JE and Cowan KH.  2009.  Gene Therapy in Oncology.  In: Clinical Oncology, 4th Edition.  Ed. M Kastan, Elsevier, Philadelphia, PA.

Talmadge JE, Reed E, Cowan K.  2009.  Tumor and iatrogenic regulation of myeloid precursors and their potential to limit immune therapy.  Immunotherapy.  1: 5-9.

Donkor MK, Lahue E, Hoke TA, Shafer LR, Coskun U, Solheim JC, Gulen D, Bishay J and Talmadge JE.  2009.  Mammary Tumor Heterogeneity in the Expansion of Myeloid-Derived Suppressor Cells.  Int Immunopharmacol (7-8):937-48.

Pande K, Ueda R, Machemer T, Sathe M, Tsai V, Brin E, Delano MJ, van Rooijen N, McClanahan TK, Talmadge JE, Moldawer LL, Phillips JH, Laface DM.  2009.  Cancer-induced Expansion and Activation of CD11b(+)Gr-1(+) Cells Predispose Mice to Adenoviral-triggered Anaphylactoid-type Reactions.  Mol Ther 17: 508-15.

Copier J, Galgleish AG, Britten C, Finke L, Gaudernack G, Gnjatic S, Kallen K, Kiessling R, Shuessler-Lenz M, Singh H, Talmadge JE, Hakansson L.  2009.  Improving the Efficacy of Immunotherapy.  Eur J Cancer 45:1424-31.

For a detailed list of publications, click here.

James E. Talmadge, Ph.D.
Dr. James E. Talmadge

Email Address
jtalmadg@unmc.edu

Mailing Address
986495 Nebraska Medical Center
Omaha, NE 68198-6495

Office Location
WHM 4014

Laboratory Location
WHM 4025

Phone Numbers
Office: 402-559-5639
Lab: 402-559-8256

Fax
402-559-4077

;